What do we do?
Our work allows cancer drugs to be efficiently produced, and delivered to cancerous tumors in a targeted fashion that doesn’t destroy the patient’s normal healthy cells indiscriminantly. We do this by simplifying and standardizing the production of antibody drug conjugates to treat cancer, using proprietary site-selective chemistries as protein modification technologies.
Who are we?
We are established scientists and medical professionals determined to treat people around world with superior, targeted cancer therapeutics.
Partnership opportunities
Leverage our novel chemistries to create your superior targeted therapeutics to treat cancer.
Investment opportunities
We have two parallel development paths: platform technology with the ability to be licensed by others and our own proprietary therapeutic products to treat cancer
Latest News and Events
ADVANCED PROTEOME THERAPEUTICS REPORTS POSITIVE RESULTS AND ADVANCES COLLABORATION WITH HEIDELBERG PHARMA
Vancouver, British Columbia / November 14, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize [...]